Mental Health and Suicide During the Menopausal Transition: Epidemiology, Mechanisms, and Policy Implications
Introduction
This report examines the epidemiology and mechanisms of mental health disorders and suicide during the menopausal transition, with a focus on depressive disorders, anxiety, sleep disturbances, and suicidal ideation/behavior across perimenopause, early postmenopause, and late postmenopause. It synthesizes quantitative estimates of prevalence, incidence, and disability-adjusted life years (DALYs), disaggregated where possible by age and sociodemographic context, and triangulates population-level burden data with cohort and case-control evidence. Mechanistic pathways are reviewed, including estrogen and progesterone fluctuations, hypothalamic–pituitary–adrenal (HPA) axis dysregulation, serotonergic modulation, vasomotor symptoms, sleep fragmentation, and immune–inflammatory pathways, alongside psychosocial and structural determinants such as caregiving stress, intimate partner violence, workplace discrimination, and cultural attitudes toward aging. Interventional evidence is assessed for hormone therapy, SSRIs/SNRIs, cognitive-behavioral and mindfulness-based therapies, and behavioral strategies like CBT-I, physical activity, and social support. Subgroups considered include surgical menopause, premature ovarian insufficiency, and comorbid chronic diseases. Outcomes include relative and absolute risks, estimation of burden metrics, and synthesis of evidence quality. The report closes with a policy brief on screening and recommendations for equitable, culturally competent prevention strategies.
Key evidence indicates: (1) a significantly elevated risk of depressive symptoms and disorders during perimenopause compared with premenopause (pooled OR ~1.40), with mixed evidence regarding postmenopause risk
Where metrics or disaggregation are limited, the report identifies evidence gaps. Visualizations are integrated when quantitative evidence allows, and all claims are supported by citations to the sources listed in this report.
Epidemiology of Mental Health Disorders During Menopausal Transition
Global burden metrics (DALYs, prevalence, incidence)
Anxiety disorders in perimenopausal women: A global analysis using Global Burden of Disease (GBD) 2021 data reports an increase in age-standardized DALY rates for anxiety disorders among women aged 45–55, from 625.51 per 100,000 in 1990 to 677.15 in 2021 (estimated average percent change 0.081, 95% CI: 0.0043–0.143), with projections to 2035 indicating a 40.67% increase to 1,180.43 per 100,000, and higher burdens concentrated in lower-SDI regions
. Depressive disorders around menopausal ages: A preprint analysis of GBD 2021 data for depressive disorders among women aged 45–54 shows absolute increases in prevalence, incidence, and DALYs from 1990 to 2021 despite stable or slightly declining age-standardized rates, with the heaviest burdens in lower-SDI regions and rising burdens in high-SDI settings
. Broader GBD assessments concur that depressive disorders are leading contributors to nonfatal burden among women, with age-specific DALY peaks near late midlife . Prevalence of depression during menopause: Systematic reviews and meta-analyses report high prevalence of depressive symptoms among menopausal women. One 2024 review pooling 55 studies (n=76,817) reported overall prevalence of 35.6% in menopausal women, with estimates of 33.9% in perimenopause and 34.9% in postmenopause, albeit with high heterogeneity and evidence of publication bias
. Another meta-analysis focused on postmenopausal women reported a pooled prevalence of 28.0% (95% CI: 25.8–30.1) and identified multiple risk and protective factors . A broader symptom-focused meta-analysis indicated wide geographic variation in psychological symptoms including depression and anxiety across menopausal stages . Incidence and relative risk across stages: A 2024 prospective cohort meta-analysis (17 studies; n=16,061) found perimenopausal women had 40% higher odds of depressive symptoms/diagnoses compared with premenopausal women (pooled OR 1.40, 95% CI: 1.21–1.61). The study found no significant elevation in postmenopause compared to premenopause
. This staged pattern is consistent with earlier cohort evidence summarized in narrative reviews . Anxiety and psychosocial interventions: A 2024 meta-analysis of 30 RCTs (n=3,501) in midlife women found psychosocial interventions reduced anxiety (overall Cohen’s d = -0.35) and depression (d = -0.30), with CBT and mindfulness-based interventions achieving statistically significant effects
.
Sleep disturbances
Sleep disturbances are highly prevalent during the menopausal transition and function as both symptom and risk pathway for mood disorders. A 2023 meta-analysis of 15 RCTs concluded that nonpharmacological interventions significantly improved sleep quality (SMD = -1.32) and reduced insomnia severity (SMD = -1.11) in perimenopausal/postmenopausal women
Suicidal ideation and mortality
Evidence on suicidality during the menopausal transition includes cohort and cross-sectional analyses as well as population vital statistics trends:
Suicidal ideation: A population-based prospective cohort from the Tokyo Teen Cohort (n=2,944 mothers) found that women who entered perimenopause after baseline had nearly double the odds of suicidal ideation at follow-up compared with premenopausal women (adjusted OR 1.92, 95% CI: 1.25–2.96); perimenopause before baseline was not significantly associated
. A large Korean occupational health cohort found dose–response increases in depressive symptoms and suicidal ideation with advancing menopausal stages compared to premenopause . A qualitative synthesis reported common experiences of suicidality during perimenopause, emphasizing barriers to appropriate care and the potential protective effect of timely hormone therapy in some cases, though without quantitative comparisons . Suicide mortality trends (United States): CDC analyses indicate that for females, the highest suicide rates are in midlife, including ages 45–54 and 45–64. An MMWR report showed that in 2020 the highest female age-specific suicide rate was among ages 45–54 (8.5 per 100,000), following an 8–19% decline from 2019 across midlife age bands
. NCHS data briefs show that female suicide rates for ages 45–64 increased from 2000 to a peak in 2015 (10.2 per 100,000), then fell to 7.9 in 2020, with a non-significant increase thereafter; across 2001–2021, this age group consistently had the highest rates among females . Provisional 2022 data indicated a 2–9% rise in female 45–54 rates compared to 2021 (not statistically significant), amid a 4% overall increase for females . Menopause timing and suicide: A nationwide Korean cohort (n=1,315,795 postmenopausal women) reported elevated suicide hazard ratios with earlier menopause: HR 1.43 for menopause <40 years (primary ovarian insufficiency), HR 1.31 for ages 40–44, and HR 1.13 for ages 45–49, compared with 50–54 as the reference; late menopause ≥55 was not significantly elevated
. A cross-sectional national survey from Korea also associated premature ovarian insufficiency and early menopause with higher odds of suicidal ideation, planning, and attempts versus premenopause . A systematic review of suicidality and menopause found mixed associations across settings, with several studies indicating higher ideation during perimenopause and others finding peaks in different stages or no association; the review emphasized methodological variability and recommended menopause-specific suicidality screening .
Visual summaries of quantitative patterns
- Figure 1 illustrates reported global age-standardized DALY rates for anxiety among perimenopausal women in 1990 and 2021 with a projection to 2035, based on published estimates
.
- Figure 2 summarizes selected U.S. female suicide rates in the 45–64 age group at several time points (2000, 2015, 2018, 2020, 2022) consistent with CDC reports of a mid-2010s peak and a decline to 2020, with a subsequent increase
.
Note: Both visual summaries reflect values and trends directly described in the cited sources and are provided to orient the reader to the magnitude and direction of change reported.
Stage-specific risks and subgroup considerations
Perimenopause vs premenopause
Depression risk is consistently elevated during perimenopause across prospective cohorts and meta-analyses, with a pooled OR of 1.40 (95% CI: 1.21–1.61) relative to premenopause
. Narrative syntheses of cohort studies similarly describe increased odds for clinically relevant depressive symptoms in early and late perimenopause . Suicidal ideation risk appears higher when women transition into perimenopause during follow-up, with one cohort reporting an adjusted OR of 1.92 compared to women remaining premenopausal
.
Postmenopause
- The 2024 cohort meta-analysis found postmenopause not significantly different from premenopause for depression risk, although large cross-sectional and occupational cohorts have reported dose–response increases in depressive symptom severity and ideation across stages, including postmenopause, compared to premenopause
. A prevalence meta-analysis in postmenopausal women estimated 28.0% depression prevalence with identifiable risk and protective factors .
Surgical menopause and premature ovarian insufficiency (POI)
- Earlier menopause timing is associated with higher suicide mortality risk in a large national cohort (HR 1.43 for POI, HR 1.31 for early menopause), suggesting that abrupt or premature estrogen loss may be a risk amplifier for suicidality
. Cross-sectional national data likewise show higher odds of suicidal ideation, planning, and attempts associated with POI and early menopause .
Comorbidity with chronic disease
- In postmenopausal women, chronic disease is a strong correlate of depression (pooled OR 3.13), and menopausal symptoms themselves double the odds of depression (OR 2.10) in pooled analyses
. Sleep-focused meta-analyses also identify chronic conditions as independent risk factors for insomnia during perimenopause (OR 1.39) . These findings support integrated management of cardiovascular, metabolic, and pain conditions to mitigate mental health burden in midlife women.
Biological Mechanisms and Interacting Pathways
Estrogen/progesterone fluctuations and neural systems
Reviews emphasize that perimenopause is characterized by large-amplitude fluctuations in estradiol and progesterone that perturb central monoaminergic systems implicated in mood regulation, particularly serotonergic circuits, and produce instability in stress responses via cross-talk between the HPG and HPA axes. A 2023 review outlines how HPA–HPG dysregulation, vasomotor symptoms, and sleep fragmentation converge to heighten risk for depressive symptoms and disorders, with potential contributions from epigenetic changes in stress- and estrogen-related genes
Vasomotor symptoms and sleep fragmentation
Vasomotor symptoms (hot flashes/night sweats) intensify sleep disruption, which is strongly associated with depressive and anxiety symptoms during the transition. Meta-analytic evidence demonstrates that hot flashes are a major risk factor for perimenopausal insomnia (OR ~2.7), and nonpharmacologic sleep interventions, including CBT/CBT-I, can substantially improve sleep quality and insomnia severity, with downstream mood benefits
Hormone sensitivity and antidepressant interactions
A randomized, placebo-controlled trial in perimenopausal women found that transdermal estradiol enhanced reward-seeking behavior (a proxy for anhedonia) among those with greater baseline “hormone sensitivity” to endogenous estradiol fluctuations, particularly in the context of recent stressors, suggesting individualized responsiveness to hormone therapy in perimenopausal mood phenotypes
Psychosocial Determinants and Structural Factors
While many epidemiologic datasets do not provide detailed stratification by race/ethnicity or socioeconomic status at the menopausal stage level, multiple sources highlight psychosocial contributors to mental health burden during midlife:
A cross-sectional study of UK women reported that early perimenopause was associated with the highest perceived stress and the greatest bother from depression and anxiety symptoms, with protective associations for resilience and self-efficacy
. A qualitative study reported themes of hopelessness, entrapment, and delayed access to appropriate care during perimenopause, with participants frequently describing improvements following access to hormone therapy and peer support, underlining the role of structural access and clinician awareness in mitigating risk
. U.S. administrative and vital statistics data indicate that midlife women bear the highest female suicide rates, with temporal declines followed by recent increases, emphasizing the intersection of mental health, socioeconomic stressors, access to care, and broader social determinants at midlife
. Primary care data from the UK highlight elevated incidence of new anxiety and depressive disorders among women ages 45–54 compared with men, and greater subsequent prescribing of SSRIs/SNRIs, suggesting both high need and engagement with health systems in this demographic
.
These findings reinforce the necessity of culturally competent, equitable preventive strategies that account for work-family stress, caregiving responsibilities, intimate partner violence, and workplace ageism/sexism. The systematic review of menopause guidelines notes that while mood disturbance is recognized as an indication for systemic menopausal hormone therapy in symptomatic women, anxiety and suicidality are rarely addressed explicitly in guideline recommendations, leaving implementation gaps in comprehensive mental health screening and care
Interventions and Clinical Management
Hormone therapy (HT)
Efficacy and timing: Evidence from network meta-analysis indicates that estrogen-containing therapies—either alone or combined with antidepressants—can reduce depressive symptoms during peri- and postmenopause, with the strongest signals in women with diagnosed depression and during earlier menopausal timing
. A mechanistic RCT suggests that “hormone sensitivity” to estradiol fluctuations may predict benefit of transdermal estradiol on anhedonia-related behavior, highlighting a potential precision-medicine approach . Cardiovascular safety and the timing hypothesis: Reviews of hormone therapy underscore the “timing hypothesis,” which posits more favorable cardiovascular profiles when therapy is initiated within 10 years of menopause onset in otherwise suitable candidates, supporting early symptomatic use but not for primary prevention of chronic disease
. Clinical guidance: A review of menopause guidelines indicates consistent recommendations for MHT to manage menopausal symptoms including mood disturbance, but not as primary treatment for clinical depression, anxiety, or suicidality; non-hormonal options (e.g., SSRIs/SNRIs) remain first-line for mood disorders per standard psychiatric practice
.
Antidepressants (SSRIs/SNRIs)
Utilization: UK primary care data show frequent prescribing of SSRIs/SNRIs following new diagnoses of anxiety and depression in women aged 45–54, suggesting broad real-world uptake
. Efficacy: The 2023 network meta-analysis supports efficacy of SSRIs, particularly when combined with HT in women with diagnosed depression during menopause
. Reviews also note limitations of SSRIs/SNRIs in addressing vasomotor and sleep symptoms, which may perpetuate mood burden unless concurrently managed .
Psychosocial and behavioral interventions
CBT/MBI: A 2024 meta-analysis of RCTs found both CBT and mindfulness-based interventions significantly reduce anxiety and depression and improve quality of life in midlife women
. CBT-I and sleep-focused therapies: Multiple syntheses and trials support CBT-I as a first-line, nonpharmacologic option for insomnia in menopause, with significant improvements in sleep quality and insomnia severity and sustained benefits
. Physical activity and lifestyle: Meta-analysis in postmenopausal women identified physical activity as protective against depression (pooled OR 0.56), supporting exercise as a core component of prevention and treatment strategies
. Complementary and botanical options: A 2025 review highlights evidence from RCTs for certain botanicals with serotonergic and anti-inflammatory actions in menopausal depression/anxiety, though head-to-head comparisons with standard treatments are limited and further mechanistic research is needed
.
Safety and contraindications
Hormone therapy: Cardiovascular, thromboembolic, and neoplastic risks require individualized assessment; guideline appraisals emphasize initiating HT near menopause for symptomatic relief when indicated and contraindication screening
. Antidepressants: While generally safe, SSRIs/SNRIs require monitoring for side effects and interactions; limitations include insufficient relief of non-mood menopausal symptoms that affect sleep and quality of life
. Special populations: Earlier menopause (POI/early menopause) and surgical menopause may confer elevated suicidality risk, underscoring the importance of proactive mental health assessment and tailored risk–benefit discussions for HT and alternative therapies
.
Structured Summaries (Tables)
Table 1: Summary of key epidemiological estimates during menopausal transition
| Domain | Metric/Result | Source |
|---|---|---|
| Perimenopausal depression risk | OR 1.40 (95% CI 1.21–1.61) vs premenopause | |
| Perimenopausal anxiety burden | ASR DALYs 1990: 625.51; 2021: 677.15; projected 2035: 1,180.43 per 100,000 | |
| Depression prevalence (menopausal women, pooled) | 35.6% overall; perimenopause 33.9%; postmenopause 34.9% | |
| Depression prevalence (postmenopause) | 28.0% (95% CI: 25.8–30.1) | |
| Insomnia risk factors (perimenopause) | Depression OR 2.73; hot flashes OR 2.70; psychotropic use OR 3.19 | |
| Suicidal ideation in perimenopause | OR 1.92 (95% CI: 1.25–2.96) if entering perimenopause after baseline vs premenopause | |
| Suicide HR by menopause timing | HR 1.43 (<40 years), 1.31 (40–44), 1.13 (45–49) vs 50–54 | |
| U.S. female suicide rate (45–64) | Peak 2015: 10.2; 2020: 7.9; 2022: ~8.6 per 100,000 (selected years) |
Table 2: Intervention evidence highlights
| Intervention | Key Finding | Source |
|---|---|---|
| Transdermal estradiol (TE2) | Benefit on reward-seeking in hormone-sensitive perimenopausal women | |
| SSRIs + HT | Largest reductions in depressive symptoms vs placebo (fluoxetine + oral HT) | |
| CBT/MBI | Reduces anxiety (d up to -0.56) and depression (d up to -0.33); QoL improves | |
| CBT-I and sleep interventions | Improves sleep quality (SMD -1.32), insomnia (SMD -1.11); durable RCT benefits | |
| Physical activity | Protective against depression in postmenopause (OR 0.56) |
Evidence Quality and Conflicts Among Sources
Depression risk during perimenopause: Stronger evidence from prospective cohorts and pooled analyses supports a significant elevation compared with premenopause
. However, some narrative reviews note limited evidence for first-onset major depressive disorder in women without prior history and emphasize subgroups with vasomotor symptoms or stress as higher risk . Suicidality: Cohort and cross-sectional studies differ in findings; the Tokyo cohort identifies increased ideation risk with perimenopause onset
, while a systematic review underscores mixed results across settings, reflecting heterogeneity in measures and designs . Mortality trends from U.S. vital statistics consistently place the highest female suicide rates in midlife, though with notable declines and subsequent increases over recent years . Early menopause increases suicide risk in a national cohort, strengthening causal plausibility regarding abrupt ovarian hormone loss as a risk amplifier . Anxiety burden: The perimenopausal anxiety DALY analysis shows slight increases historically with substantial projected growth by 2035
. This complements RCT meta-analytic evidence for psychosocial therapies reducing anxiety in menopausal populations . Sleep interventions: Converging RCT and meta-analytic evidence supports CBT-I and nonpharmacologic interventions for insomnia in midlife women, with large effects on sleep measures and likely indirect benefits on mood
. Guideline and evidence grading: A review of guidelines using AGREE II shows recognition of mood disturbance as an HT indication in symptomatic women but lack of explicit recommendations for anxiety or suicidality; none of the included systematic reviews explicitly reported GRADE certainty ratings for perimenopausal mood/anxiety/suicidality outcomes, and one suicidality review assessed quality using QATSDD rather than GRADE
. These gaps underscore the need for standardized outcome definitions, stage-specific analyses, and formal certainty grading in future syntheses.
Policy Brief: Screening and Prevention in Primary Care and Gynecology
Rationale
Elevated risk of depressive symptoms during perimenopause versus premenopause supports routine, stage-aware screening in primary care and gynecology
. Increased suicidal ideation upon transition to perimenopause in a longitudinal cohort, higher midlife female suicide mortality rates, and heightened risk associated with earlier menopause support proactive suicidality screening and monitoring during the transition and in women with early/surgical menopause
. High prevalence of depression and insomnia during menopause and strong links between vasomotor symptoms, sleep disturbances, and mood underscore integrated screening for comorbid symptoms and contributing factors
.
Recommended screening tools and workflows
Depression: PHQ-9 for initial screening and monitoring symptom severity; repeat at regular intervals during perimenopause and early postmenopause, and at any time in symptomatic women (rationale based on high prevalence and increased risk during transition, as above)
. Anxiety: GAD-7 for screening and severity monitoring, given evidence for anxiety symptom burden and responsiveness to psychosocial interventions
. Suicidality: A structured assessment such as the Columbia-Suicide Severity Rating Scale (C-SSRS) at baseline when significant mood or sleep complaints are present, at the initiation of perimenopause symptoms, and during high-risk contexts (e.g., early menopause, surgical menopause, prior psychiatric history, or severe vasomotor/sleep disturbances) given cohort and population-level signals described above
. Sleep: Insomnia Severity Index (ISI) or Pittsburgh Sleep Quality Index (PSQI) for women reporting sleep difficulties, in light of high prevalence and effective nonpharmacological treatments
.
Care pathways
Integrated management of vasomotor symptoms (e.g., with guideline-concordant HT when indicated and safe) and insomnia (with CBT-I where available), alongside mood/anxiety treatments (e.g., SSRIs/SNRIs, CBT/MBI)
. Individualized HT consideration in women with prominent mood disturbance during perimenopause and in those with hormone sensitivity phenotypes, with risk assessment aligned to timing and cardiometabolic profiles
. Proactive referrals for psychotherapy (CBT/MBI/CBT-I) and community resources (peer support, caregiver support services) together with structural interventions (workplace accommodations for vasomotor and sleep issues, violence screening and referral)
. Close monitoring and safety planning for suicidality in women with perimenopause-onset ideation, early/surgical menopause, severe comorbidity burden, or prior psychiatric history, in coordination with mental health services
.
Equity and cultural competence
Address barriers to HT, psychotherapy (including CBT-I), and specialist care for underrepresented groups and low-resource settings where anxiety/depression burden may be higher and access limited, as indicated by higher DALYs in low-SDI regions and heterogeneous prevalence across regions
. Implement culturally sensitive education on menopausal mental health and aging, address workplace ageism/sexism with supportive policies, and incorporate screening for intimate partner violence and caregiving stress within routine midlife care pathways
.
Limitations
Disaggregation by race/ethnicity and socioeconomic status is limited across many studies; future research should stratify by these determinants. Some estimates (e.g., menopausal stage-specific DALYs beyond anxiety) rely on age-banded GBD analyses and cannot isolate perimenopause with high precision
. Systematic reviews on suicidality report mixed associations across menopausal stages, reflecting heterogeneity in measures and design; formal GRADE assessments are uncommon, limiting certainty grading
. Prevalence meta-analyses of depression display high heterogeneity, potential publication bias, and variation by measurement tool and study design; cautious interpretation is warranted
. Some interventional evidence, including combined HT and SSRIs or individualized estradiol approaches, remains limited in size or scope, necessitating larger randomized trials with diverse populations and longer follow-up to evaluate benefits and risks across subgroups
.
Conclusion
Across multiple evidence streams, perimenopause emerges as a period of elevated risk for depressive symptoms and disorders relative to premenopause, with strong associations between vasomotor symptoms, sleep disturbances, and mood. Anxiety contributes substantially to the burden of disease in perimenopausal women globally, with rising DALY trends and projections indicating growing needs, particularly in lower-SDI regions. Suicidality warrants attention: longitudinal data indicate increased suicidal ideation upon transition into perimenopause, midlife women bear the highest female suicide mortality rates in U.S. data, and earlier menopause timing elevates suicide risk—patterns that collectively justify routine suicidality assessment during the menopausal transition and in early or surgical menopause.
Clinical management should integrate symptom-targeted HT when appropriate, evidence-based psychotherapy (CBT and MBI), and sleep-focused interventions (CBT-I), with antidepressants used per standard indications and considered in combination with HT for diagnosed depression during perimenopause. Equity-focused implementation—including improved access to HT, CBT/CBT-I, sleep care, and social supports—along with culturally competent education and structural interventions addressing workplace and interpersonal risks, is essential. Improved disaggregation by race/ethnicity and socioeconomic status, standardized stage definitions, formal evidence grading (e.g., GRADE), and longitudinal studies of suicidality will strengthen future guidance.
TLDR
Risk: Perimenopause is associated with a 40% higher odds of depressive symptoms/diagnoses versus premenopause, while evidence for postmenopause is mixed
. Anxiety burden measured by DALYs has risen since 1990 in perimenopausal women with projections of a >40% increase by 2035 . Depression prevalence among menopausal women is high (pooled ~28–36%), with heterogeneity across regions and methods . Sleep: Insomnia and sleep problems are common and tightly linked to mood symptoms; CBT-I and nonpharmacological interventions show substantial benefits
. Suicidality: Transition into perimenopause is associated with higher suicidal ideation in a longitudinal cohort; midlife female suicide rates are the highest among female age groups in U.S. vital statistics, and earlier menopause timing increases suicide mortality risk
. Mechanisms: Estradiol/progesterone fluctuations interact with serotonergic and stress-response systems; vasomotor symptoms and sleep fragmentation are key pathways; neuroinflammation and reduced neurotrophic signaling may also contribute
. Interventions: Evidence supports combined HT and SSRIs for diagnosed depression during perimenopause, individualized estradiol benefits for hormone-sensitive phenotypes, CBT/MBI for mood symptoms, and CBT-I for insomnia; physical activity is protective
. Policy: Implement routine, stage-aware screening (PHQ-9, GAD-7, C-SSRS; ISI/PSQI for sleep) in primary care and gynecology; integrate symptom-targeted HT, psychotherapy, and sleep care; address disparities via equitable access, culturally competent education, and structural supports
.